Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Platinum-resistant Ovarian Cancer: early-phase trial registry
11 of 18 indexed Platinum-resistant Ovarian Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 11 currently recruiting · #953 of 28,707 conditions by registered trial count
Platinum-resistant Ovarian Cancer: 18 US clinical trials tracked, 11 recruiting.
Platinum-resistant Ovarian Cancer is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Mersana Therapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition platinum-resistant-ovarian-cancer
OPEN 11 | RECR 61% | LATE 3 | EARLY 15 | RANK #953 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Breast Cancer Metastatic (61% recruiting · 18 trials)
Platinum-resistant Ovarian Cancer lists 11 open slots (61% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Platinum-resistant Ovarian Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Platinum-resistant Ovarian Cancer is recruiting above its size-band peers.
11 of 18 indexed trials (61.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Platinum-resistant Ovarian Cancer research.
Mersana Therapeutics accounts for 3 of 18 trials (16.7%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Platinum-resistant Ovarian Cancer enrolment sits around 142 participants.
Median target enrolment is 142 among the 18 trials that report a genuine target (sentinel values excluded). 8 of those (44.4%) plan for fewer than 100 participants.
-
Platinum-resistant Ovarian Cancer research is mostly interventional.
18 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Whitehawk Therapeutics
NCT07470853
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Whitehawk Therapeutics
NCT07444814
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
NCT05281471
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Stemline Therapeutics
NCT07226427
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics
NCT06515613
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
MacroGenics
NCT06730347
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Cybrexa Therapeutics
NCT06315491
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Outpace Bio
NCT07030907
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
TILT Biotherapeutics
NCT05271318
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
ImmunityBio
NCT06710288
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
NCT06321484
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Genmab
NCT06619236
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Mersana Therapeutics
NCT03319628
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Novita Pharmaceuticals
NCT07109414
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Ascendis Pharma Oncology Division A/S
NCT05081609
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Cordgenics
NCT03949283
First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b
Mersana Therapeutics
NCT06517485
First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b
Mersana Therapeutics
NCT06517433
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 4 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Platinum-resistant Ovarian Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Platinum-resistant Ovarian Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Platinum-resistant Ovarian Cancer page
18 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Platinum-resistant Ovarian Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mersana Therapeutics sponsors the most Platinum-resistant Ovarian Cancer trials on record, review their full trial history before evaluating a specific study. See Mersana Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Platinum-resistant Ovarian Cancer condition card totals 18 registered trials; most-linked intervention upifitamab rilsodotin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.